Iodofiltic acid I-123 - Molecular Insight Pharmaceuticals

Drug Profile

Iodofiltic acid I-123 - Molecular Insight Pharmaceuticals

Alternative Names: 15-(4-Iodophenyl)-3-methylpentadecanoic acid; 123I-BMIPP; BIO 110; BMIPP; Cardiodine; MyoImage; Zemiva

Latest Information Update: 26 Sep 2013

Price : $50

At a glance

  • Originator Molecular Insight Pharmaceuticals; Nihon Medi-Physics
  • Class Fatty acids; Imaging agents; Iodinated contrast media; Iodobenzenes; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Ischaemic heart disorders
  • No development reported Myocardial ischaemia

Most Recent Events

  • 26 Sep 2013 No development reported - Phase-II for Myocardial ischaemia in Canada (Injection)
  • 26 Sep 2013 No development reported - Phase-II for Myocardial ischaemia in USA (Injection)
  • 22 Jan 2013 Molecular Insight Pharmaceuticals has been acquired by Progenics Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top